Compare Bristol-Myers Squibb Co (BMY) vs DraftKings Inc (DKNG) Price & Performance

Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.

The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.

DraftKings (DKNG) trades at $24.27, up 1.0% today, showing mixed technical signals with a bullish overall trend but bearish moving averages. Fundamentally, the company achieved its first annual net profit in 2025 ($4M) after years of losses, with revenue growing to $6.05B. However, recent quarterly earnings have missed expectations, and valuation ratios remain elevated with a P/E of 246.33. Analyst sentiment remains positive with 73% buy ratings and a $34 consensus price target, representing 40% upside potential.

The outlook for DKNG hinges on successful execution in prediction markets and sportsbook growth, particularly with the upcoming NFL season. Key risks include intense competition from prediction market platforms, regulatory challenges, and the company's ability to maintain profitability after recently turning profitable. While technical indicators show near-term resistance at $25, the substantial analyst upside and improving cash flow trends suggest potential for long-term growth if execution improves.